Register today for our presentations from WRIB 2016


Register today to receive a copy of our presentations from the 2016 Workshop on Recent Issues in Bioanalysis (WRIB) post-event.

Q2 Solutions is committed to being both an active member of the bioanalytical community and a trusted partner to our customers. We aim to share ideas, best practices, and learnings to advance the field.  

A this year’s WRIB we will be leading two training session that cover some of the latest thinking around biomarkers and LBA/LCMS.  

2016 Q2 Solutions’ WRIB Training Sessions
  • Monday April 18, 8am-5pm: “Robustness of Hybrid LBA/LCMS Assays in a Regulated Environment” by Barry Jones, Training Course M-2 for LCMS scientists
  • Friday April 22, 8am-5pm: “Current Best practices in Commercial Kits Evaluation/Validation for Biomarker Assays” by Paul Rhyne, Training Course F-1
Register to receive a copy of our presentations after WRIB.

At Q2 Solutions we have the latest technologies to support your project, and the scientific acumen and leadership to effectively implement the right strategies and insights for better outcomes. Our approach ensures you get the highest quality data you need when you need it – giving you reliable, quality data for better decision-making, faster, more efficient drug development, and higher quality regulatory submissions. Learn more

Meet the Authors

Barry Jones, Ph.D, Manager, LCMS Biologics and Biomarkers

Barry JonesDr. Barry Jones joined Advion Biosciences in 2007, began the LCMS Biologics Group in 2008 under Dr. Gary Schultz, and now leads the large molecule LCMS method development group at Q2 Solutions. Research within the LCMS biologics group at Q2 Solutions is focused on targeted quantitative LC-MS/MS analysis of endogenous biomolecules and large molecule biotherapeutics on triple quadrupole and orbitrap instruments. Dr. Jones is particularly interested in the application of hybrid Immunoaffinity-LC-MS/MS methods to high-throughput bioanalysis, as well as the scientific challenges and regulatory strategies for validation of LCMS biomarker assays supporting drug development in a regulated environment.

Prior to joining Q2 Solutions, Dr. Jones led the Mass Spectrometry Facility at Binghamton University, N.Y. using Q-TOF and MALDI mass spectrometry and nanoESI techniques in support of proteomic research. He earned his Ph.D. in Physical Chemistry at Binghamton University in 2006.

Paul Rhyne, Ph.D, Scientific Director, Immunoassay Services

Paul RhyneDr. Rhyne, currently leads a bioanalytical group for Q2 Solutions, a Quintiles Quest joint venture. Dr. Rhyne has more than 15 years of scientific leadership experience in laboratory operations, clinical biomarkers, large molecule PK analysis, and Immunogenicity assessment. He obtained his Ph.D. at the University of Tennessee Memphis and completed 3 years of post-doctoral studies at St. Jude Children’s Research Hospital.

Dr. Rhyne was an Associate Director at Bristol-Myers Squibb Company, a Senior Director at Tandem laboratories, and has held many senior leadership positions at Upstate Biotechnology and Amplistar Inc. A noted industry expert in clinical biomarkers and large molecule bioanalytical analysis, and has published many scientific publications in peer reviewed journals. Dr. Rhyne is an active member of the American Association of Pharmaceutical Scientists including serving on programming committees, steering committee for translational biomarker focus group, and chair of the biomarker discussion group.